This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Drugs

Novo Nordisk (NVO) Stock Gains Today on Drug Application Resubmission

Novo Nordisk (NVO) Stock Gains Today on Drug Application Resubmission

  • Tickers in this article:
  • NVO

Novo Nordisk (NVO) shares rose today as the company prepares to reapply for approval of its insulin treatment Tresiba.

03/26/15 - 04:01 PM EDT

ZS Pharma, Gilead & Anacor: BioTech Stock Picks on Sell-Off

Biotech stocks are once again lower after leading Wednesday's market sell-off as investors jump out of the sector as fast as they can.

03/26/15 - 11:39 AM EDT

Try Jim Cramer's Action Alerts PLUS
Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing

Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing

If history repeats itself, the recent weakness in biotech stocks will end with lots more buying.

03/26/15 - 07:17 AM EDT

What Institutional Options Flow Signaled in Kraft Prior to Merger

What Institutional Options Flow Signaled in Kraft Prior to Merger

Henry Schwartz, President of Trade Alert, says options order flow was very quiet into the deal announcement, but looking further back, interesting call volume on March 10 was detected.

03/25/15 - 02:11 PM EDT

Kofax Jumps 46% on Lexmark Deal, Tesla Slides on Downgrade

Kofax Jumps 46% on Lexmark Deal, Tesla Slides on Downgrade

Major U.S. benchmarks are all trading narrowly lower as both the dollar and latest economic data weight on traders.

03/25/15 - 11:49 AM EDT

Novavax (NVAX) Stock Declines Today After Announcing $175 Million Public Stock Offering

Novavax (NVAX) Stock Declines Today After Announcing $175 Million Public Stock Offering

  • Tickers in this article:
  • NVAX

Novavax (NVAX) shares are falling after the company announced a $175 million share repurchase program.

03/25/15 - 10:47 AM EDT

Merck (MRK) Stock Gains Today on Positive Phase III Melanoma Treatment Study Results

Merck (MRK) Stock Gains Today on Positive Phase III Melanoma Treatment Study Results

  • Tickers in this article:
  • MRK

Merck (MRK) shares are rising after it halted its phase 3 melanoma treatment study due to positive results.

03/24/15 - 10:59 AM EDT

High Alert for Signs of Biotech Collapse Makes for Nervous Investors

High Alert for Signs of Biotech Collapse Makes for Nervous Investors

Biotech stocks may or may not be in a bubble, but investors are definitely worried about sky-high valuations.

03/24/15 - 08:56 AM EDT

Gilead Sciences (GILD) Stock Declined Today on Hepatitis C Treatment Warning

Gilead Sciences (GILD) Stock Declined Today on Hepatitis C Treatment Warning

  • Tickers in this article:
  • GILD

Gilead Sciences (GILD) shares fell in intraday trading after the company sent a letter to healthcare providers warning them of a potential fatal hepatitis C drug reaction.

03/23/15 - 04:53 PM EDT

Eli Lilly (LLY) Stock Gains Today After FDA Lifts Ban on Pain Treatment Drug Trials

Eli Lilly (LLY) Stock Gains Today After FDA Lifts Ban on Pain Treatment Drug Trials

  • Tickers in this article:
  • LLY

Eli Lilly (LLY) shares are gaining today after the FDA lifted its temporary ban on clinical trials of pain drugs that block the nerve growth factor protein.

03/23/15 - 03:21 PM EDT

11 Promising New Drugs Expected to Make Billions in Sales

11 Promising New Drugs Expected to Make Billions in Sales

Big pharmaceuticals companies are expected to unveil lots of promising drug therapies in 2015 - specifically drugs that could make billions in sales within five years.

03/23/15 - 02:58 PM EDT

Vertex Cystic-Fibrosis Drug Smacked by Burden of High Expectations

Vertex Cystic-Fibrosis Drug Smacked by Burden of High Expectations

  • Tickers in this article:
  • VRTX

Vertex disclosed some new phase IIb study results that raise concerns VX-661 may not be as potent as previously hoped.

03/23/15 - 09:07 AM EDT

Which Sectors Win on Continued Fed Dovishness: Best of Kass

Which Sectors Win on Continued Fed Dovishness: Best of Kass

In highlights from his trading diary of the past week, Kass discusses what a noted March Madness coach taught him about investing, and which sectors win on continued Fed dovishness.

03/22/15 - 01:59 PM EDT

Biogen, Alzheimer's and the Biotech Mania (Is It a Bubble?)

Biogen, Alzheimer's and the Biotech Mania (Is It a Bubble?)

Biogen shares are up on strong Alzheimer's drug data, but is the biotech bull market making investors forget about risk?

03/20/15 - 12:29 PM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs